Business
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx\n\nViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx\n\n\nViaDerma's Manufacturer has completed the first run of its topical antibiotic being sold as VitaStem by its Sales, Marketing and Distribution Partner Biogenx, Inc.; Distribution will begin as the product is shipped to Distribution points in Florida and Abroad \n\n LOS ANGELES, CA--(Marketwired - October 19, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun distribution of its highly anticipated topical antibiotic ointment. Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStem™, which retails for $99 and can be purchased online at www.Biogenx.net. The Company's manufacturing partner has completed the first production run of 15,000 units of the product overcoming several manufacturing delays. The Company expects to ramp up production on a monthly basis and the first orders shipped out yesterday. Since the promising results of clinical studies of VitaStem in hospital groups in Japan and the Philippines, the Company will send a portion of the first run to Japan and the Philippines. The Distributors are also interested in ViaDerma's several follow-on products, using ViaDerma's proprietary solution, which the Company is expecting additional FDA registration numbers throughout the rest of 2017. The Company's President, Dr. Christopher Otiko said, \"Now that the product delays are over and we are in the distribution phase we expect the orders to come in from several key countries abroad. The quick response by customers in our marketing studies has shown positive results and this has led to an increased interest in our products due to the need in several markets around the world. This should open the door for future products in several key markets. Our contract manufacturer has the capabilities to manufacture most of our products and we look forward to building a lasting relationship to deliver high quality pharmaceuticals to our distributors.\"About ViaDe...